Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: Correlation between composition and therapeutic efficacy

Thrombosis Research

Volumn 107, Issue SUPPL., 2002, Pages S3-

  Hellstern, Peter ^a   Haubelt, Hannelore ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Clinical trials; Conditions of manufacture; Efficacy; Methylene blue light treated plasma; Quarantine stored fresh frozen plasma; Solvent detergent treated plasma

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; CITRIC ACID; DETERGENT; FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMA PROTEIN; SOLVENT;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD DONOR; COLD EXPOSURE; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG STORAGE; DRUG TOLERABILITY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; INFECTION RISK; LEUKOCYTE; LOW TEMPERATURE; PRIORITY JOURNAL; SCREENING; VIRUS DETECTION; VIRUS INACTIVATION; BLOOD COMPONENT THERAPY; BLOOD STORAGE; INSTRUMENT STERILIZATION; METHODOLOGY; PLASMA; REVIEW; STANDARD; TREATMENT OUTCOME; VIROLOGY;

BLOOD COAGULATION FACTORS; BLOOD COMPONENT TRANSFUSION; BLOOD PRESERVATION; HUMANS; PLASMA; STERILIZATION; TREATMENT OUTCOME;

EID: 0037206603     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00145-7     Document Type: Conference Paper

References (56)

1. Rock G., Tittley P., Fuller V. Effect of citrate anticoagulants on factor VIII levels in plasma. Transfusion. 28:1988;248-252.
2. Beeck H., Becker T., Kiessig S.T., Kaeser R., Wolter K., Hellstern P. The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: a prospective study. Transfusion. 39:1999;1266.
3. Prowse C., Waterston Y.G., Dawes J., Farrugia A. Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang. 52:1987;257-264.
4. Suontaka A.M., Åkerblom O., Blombäck M., Eriksson L., Högman C.F., Payrat J.M. Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant. Vox Sang. 71:1996;97-102.
5. Solheim B.G., Bergerud U.E., Kjeldsen-Kragh J., Brosstad F., Mollnes T.E., Högman C.F.et al. Improved blood preservation with 0.5CPD Erythro-Sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood. Vox Sang. 74:1998;168-175.
6. Duguid J., Winkelman L., Feldman P., Brady A.M. The effect of citrate anticoagulants on apheresed plasma. Transfus. Sci. 10:1989;287-293.
7. Evans D., Walker T., Evans H. Pilot scale (300 kg) fractionation of plasma for factor VIII and factor IX. Transfus. Sci. 10:1989;313-319.
8. Smith J.F., Ness P.M., Moroff G., Luban N.L. Retention of coagulation factors in plasma frozen after extended holding at 1-6 degrees C. Vox Sang. 78:2000;28-30.
9. Wensley R.T., Snape T.J. Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield. Vox Sang. 38:1980;222-228.
10. Gu Y.J., van Oeveren W. Activation of plasma components by leukocyte removal filters. ASAIO J. 40:1994;M598-M601.
11. Riggert J., Simson G., Dittmann J., Köhler M. Prestorage leukocyte depletion with in-line filtration of whole blood in comparison with blood component leukocyte depletion. Vox Sang. 69:1995;201-205.
12. Rapaille A., Moore G., Siquet J., Flament J., Sondag-Thull D. Prestorage leukocyte reduction with in-line filtration of whole blood: evaluation of red cells and plasma storage. Vox Sang. 73:1997;28-35.
13. Riggert J., Schwartz D.W., Wieding J.U., Mayr W.R., Köhler M. Prestorage inline filtration of whole blood for obtaining white cell-reduced blood components. Transfusion. 37:1997;1039-1044.
14. Mayr W.R., Köhler M. Current status of solvent/detergent-treated frozen plasma, whole-blood inline filtration, and Creuzfeldt-Jakob disease. Transfusion. 39:1999;107.
15. Cardigan R., Sutherland J., Garwood M., Krailadsiri P., Seghatchian J., Beard M.et al. The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br. J. Haematol. 114:2001;233-240.
16. Carlebjork G., Blomback M., Pihlstedt P. Freezing of plasma and recovery of factor VIII. Transfusion. 26:1986;159-162.
17. Akerblom O., Bremme K., Dackland A.L., Fatah K., Suontaka A.M., Blomback M. Freezing technique and quality of fresh-frozen plasma. Infus.ther. Transfus.med. 19:1992;283-287.
18. Koerner K., Stampe D. Stability of blood coagulation factors in deep frozen fresh plasma by storage at -20 degrees C and -40 degrees C. Infus.ther. Klin. Ernahr. 11:1984;46-50.
19. Riggert J., Mörsdorf S., Pindur G., Köhler M., Seyfert U.T. Quality of fresh-frozen plasma during storage. Vox Sang. 73:1997;257.
20. Kotitschke R., Morfeld F., Kirchmaier C.M., Koerner K., Köhler M. Stability of fresh frozen plasma: results of 36-month storage at -20°C, -25°C, -30°C and -40°C. Infus.ther. Transfus.med. 27:2000;174-180.
21. Illert W.E., Butsch H., Nuber D., Howe J., Sänger W., Weidinger S. Long-term storage of fresh frozen plasma at -40°C. A multicenter study on the stability of labile coagulation factors over a period of 3 years. Infus.ther. Transfus.med. 28:2001;189-194.
22. Horowitz B., Bonomo R., Prince A.M., Chin S.N., Brotman B., Shulman R.W. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 79:1992;826-831.
23. Beeck H., Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang. (SV):1998;219-223.
24. Hellstern P., Sachse H., Schwinn H., Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang. 63:1992;178-185.
25. Solheim B.G., Rollag H., Svennevig J.I., Fosse E., Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion. 40:2000;84-90.
26. Hellstern P., Biesert L., Robinson S., Schwinn H. Virus partitioning into hydrophobic phases: a novel method of virus removal for plasma products. Infus.ther. Transfus.med. (SV):1995;36.
27. Haubelt H., Blome M., Kiessling A.H., Isgro F., Bach J., Saggau W.et al. Effects of solvent/detergent-treated plasma and fresh frozen plasma on hemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang. 82:2002;9-14.
28. Lutze G., Hartung K.J. Gerinnungsfaktoren-Aktivitäts-und Konzentrationsbestimmungen in konventionellen und virusinaktivierten gerinnungsaktiven Plasmen. Krankenhauspharmazie. 15:1994;517-522.
29. Leebeek F.W.G., Schipperus M.R., van Vliet H.H.D.M. Coagulation factor levels in solvent/detergent-treated plasma. Transfusion. 39:1999;1150-1151.
30. Mast A.E., Stadanlick J.E., Lockett J.M., Dietzen D.J. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood. 94:1999;3922-3927.
31. Billing Clason S., Meijer P., Kluft C., Ersdal E. Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures. Blood Coagul. Fibrinolysis. 10:1999;487-494.
32. Gallimore M.J., Aurell L., Friberger P., Gustavsson S., Rees W.A. Chromogenic peptide substrate assays for determining functional activities of α2-macroglobulin and α1-antitrypsin using a new trypsin substrate [abstract]. Thromb. Haemost. 50:1983;230.
33. Allford S.L., Harrison P., Lawrie A.S., MacKie I.J., Machin S.J. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br. J. Haematol. 111:2000;1215-1222.
34. Lambrecht B., Mohr H., Knüver-Hopf J., Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang. 60:1991;207-213.
35. Zeiler T., Riess H., Wittmann G., Hintz G., Zimmermann R., Müller C.et al. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion. 34:1994;685-689.
36. Simonsen A.C., Sørensen H. Clinical tolerance of methylene blue virus-inactivated plasma. Vox Sang. 77:1999;210-217.
37. AuBuchon J.P., Pickard C., Herschel L., O'Connor J.L., Lee E. Removal of methylene blue from plasma via an adsorbent filter. Vox Sang. 74:1998;1-6.
38. Riggert J., Humpe A., Legler T.J., Wolf C., Simson G., Köhler M. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. Transfusion. 41:2001;82-86.
39. Mohr H. Inactivation of viruses in human plasma. Methods Enzymol. 319:2000;207-216.
40. Aznar J.A., Molina R., Montoro J.M. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion. 39:1999;748-750.
41. Aznar J.A., Bonanad S., Montoro J.M., Hurtado C., Cid A.R., Soler M.A.et al. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang. 79:2000;156-160.
42. Wieding J.U., Hellstern P., Köhler M. Inactivation of viruses in fresh-frozen plasma. Ann. Hematol. 67:1993;259-266.
43. Wagner S.J., Cifone M.A., Murli H., Dodd R.Y., Myhr B. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion. 35:1995;407-413.
44. Hellstern P., Larbig E., Walz G.A., Thürigen W., Oberfrank K. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infus.ther. Transfus.med. (SV):1993;16-18.
45. Inbal A., Epstein O., Blickstein D., Kornbrot N., Brenner B., Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul. Fibrinolysis. 4:1993;599-604.
46. Solheim B.G., Svennevig J.L., Mohr B., Dragsund M., Noddeland H., Töllefsrud S.et al. The use of Octaplas in patients undergoing open heart surgery. Müller-Berghaus G. DIC: pathogenesis, diagnosis and therapy of disseminated intravascular fibrin formation. 1993;253-262 Elsevier, Amsterdam.
47. Horowitz M.S., Pehta J.C. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang. (SV):1998;231-235.
48. Williamson I.M., Llewelyn C.A., Fisher N.C., Allain J.P., Bellamy M.C., Baglin T.P.et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 39:1999;1227-1234.
49. Wieding J.U., Rathgeber J., Zenker D., Pohl U., Köhler M. Prospective, randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma. Transfusion. (SV):1999;23.
50. Beck K.H., Mortelmans Y., Kretschmer V., Höltermann W., Lukasewitz P. Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infus.ther. Transfus.med. 27:2000;144-148.
51. Lerner R.G., Nelson J., Scorcia E., Grima K., Kancherla R.R., Zarou-Naimo C.M.et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang. 79:2000;161-167.
52. Sarode R., Yomtovian R. Efficacy of SD-treated plasma during liver transplantation. Transfusion. 40:2000;886.
53. Flamholz R., Jeon H.R., Baron J.M., Baron B.W. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep vein thromboses? J. Clin. Apher. 15:2000;169-172.
54. Rizvi M.A., Vesely S.K., George J.N., Chandler L., Duvall D., Smith J.W.et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion. 40:2000;896-901.
55. De Jonge J., Groenland T.H.N., Metselaar H.J., Ijizermans J.N.M., van Vliet H.H.D.M., Visser L.et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth. Analg. 2002;1127-1131.
56. Baudoux E., Margraff U., Coenen A., Jacobs X., Strivay M., Lungu C.et al. Hemovigilance: tolerance of solvent-detergent treated plasma. Vox Sang. (SV):1998;237-239.